Compare Cassava Sciences Inc (FLNA) vs InMode Ltd (INMD) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

INMD trades at $14.01, up 0.14% on the day, with a bearish technical signal from moving averages and oscillators. The company reported Q2 2026 earnings of $0.35 per share, beating expectations, and maintains a strong gross profit margin of 76.52%. Recent news includes the launch of Morpheus8 Cool and an unsolicited acquisition offer from Steel Partners at $16.75 per share.

The outlook is mixed: valuation metrics like P/E of 11.63 and EV/EBITDA of 4.48 appear attractive, but declining net income and bearish technicals pose risks. Analyst consensus is divided with 45.45% buy ratings, highlighting potential upside from strategic developments against execution challenges.